Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection
Brief Summary: The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is, pegylated-interferon-alfa-2a and ribavirin in treatment-naive (never been treated before with antiretroviral therapy) participants.


Options:
A: Arm Label: Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Placebo+Pegylated-interferon-alfa-2a+Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated-interferon-alfa-2a, Drug: Placebo, Drug: Ribavirin | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon-alfa-2a; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin
B: Arm Label: Placebo + Peg-IFN/Ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin, Drug: Comparator: placebo | Intervention Type: DRUG; Name: Comparator: Vaniprevir; Assigned to Arm(s): Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Pegylated-Interferon (Peg-IFN); Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Ribavirin; Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin
C: Arm Label: LDV/SOF 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 12 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 Week, LDV/SOF 8 Week, LDV/SOF+RBV 8 Week | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 8 Week
D: Arm Label: A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk

Answer: A